To further analyze whether apatinib inhibited NSCLC cells via STAT3 signaling, we treated A549 and H1299 cells with apatinb after pretreatment of 20 ng/mL interleukin-6 (IL-6), a major mediator of inflammation and activator of STAT3. The gene discussed is STAT3; the disease is non-small cell lung carcinoma.